Form 4: Twist Bioscience CFO Receives RSU Award

Twist Bioscience's Chief Financial Officer, Adam Laponis, was granted 32,648 restricted stock units, vesting quarterly over four years.

Summary

• Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (TWST), was granted 32,648 shares of Common Stock in the form of a Restricted Stock Unit (RSU) award.
• The transaction date for this acquisition was November 18, 2025.
• The RSUs will vest at a rate of 1/16th of the total number of units on each quarterly anniversary of November 20, 2025, over a total vesting period of 48 months.
• Vesting is contingent upon Mr. Laponis's continuous service to the company through each vesting date.
• Following this reported transaction, Mr. Laponis beneficially owns 143,656 shares of Common Stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is a standard practice for aligning management incentives with shareholder interests and promoting long-term retention, generally viewed positively as a component of a robust compensation strategy.

Positives

• The RSU award aligns the Chief Financial Officer's long-term financial interests with those of the shareholders, encouraging sustained performance.
• Equity compensation serves as an incentive for the retention of key management personnel, ensuring continuity in leadership.

Negatives

• The future issuance of shares upon RSU vesting will result in a minor dilution of existing shareholder equity.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the vesting schedule of the granted equity.

Industry Context

The grant of restricted stock units to executive officers is a common practice across the biotechnology and technology sectors to attract, retain, and incentivize key talent, aligning their performance with long-term company success.

Comparison to Industry Standards

• Equity compensation, particularly through restricted stock units, is a standard component of executive compensation packages in the life sciences and technology industries, comparable to practices at companies like Illumina or Ginkgo Bioworks.

Related Party Transactions

• Grant of 32,648 Restricted Stock Units to Chief Financial Officer Adam Laponis as part of his executive compensation package.

Stakeholder Impact

• Shareholders: Potential minor dilution from future share issuance upon RSU vesting; improved alignment of the CFO's interests with the company's long-term performance and value creation.
• Employees: Standard equity compensation practices can positively influence overall employee morale and retention by demonstrating a commitment to competitive compensation.

Next Steps

• Continued vesting of the 32,648 RSUs over the next 48 months, subject to Adam Laponis's continuous service.

Key Dates

Keywords

Twist Bioscience, TWST, Adam Laponis, CFO, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, Form 4